Coya Therapeutics, Inc. (COYA)
| Market Cap | 70.37M -44.8% |
| Revenue (ttm) | 4.69M +17.6% |
| Net Income | -30.17M |
| EPS | -1.40 |
| Shares Out | 23.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 99,179 |
| Open | 3.175 |
| Previous Close | 3.130 |
| Day's Range | 2.962 - 3.175 |
| 52-Week Range | 2.720 - 6.620 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 15.21 (+407.0%) |
| Earnings Date | Nov 10, 2026 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatm... [Read more]
Financial Performance
In 2025, Coya Therapeutics's revenue was $7.95 million, an increase of 123.57% compared to the previous year's $3.55 million. Losses were -$21.23 million, 42.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price target is $15.21, which is an increase of 407.00% from the latest price.
News
Coya Therapeutics reports Q3 EPS (45c), consensus (35c)
Reports Q3 revenue $234,134, consensus $78,570. “Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of…
Coya Therapeutics sees cash runway into 2H27
As of September 30, 2026, Coya had cash and cash equivalents of $35.8 million, sufficient to fund operations, as currently planned, past the Phase 2/3 ALSTARS topline data readout and…
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Earnings release: Q3 2026
Coya Therapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Coya Therapeutics Quarterly report: Q3 2026
Coya Therapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Coya Therapeutics announces poster presentation on NfL biomarker methodology
Coya Therapeutics (COYA) announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomize...
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a p...
Coya Therapeutics to initiate OLE of Phase 2/3 ALSTARS trial of COYA 302
Coya Therapeutics (COYA) announced plans to initiate an open-label extension, OLE, of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis. Coya plans to…
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302
Coya Therapeutics (COYA) announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTL...
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial
Coya Therapeutics (COYA) announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CT...
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya announces publication of preclinical study on effects of COYA 303
Coya Therapeutics (COYA) announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, “The…
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announc...
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Coya Therapeutics reports Q2 EPS (28c), consensus (36c)
Reports Q2 revenue $243.7k, consensus $104.29k. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coy...
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Quarterly report: Q2 2026
Coya Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Coya Therapeutics Earnings release: Q2 2026
Coya Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.